Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease - PubMed

3 months ago

Alzheimer's disease (AD) is the leading cause of age-associated dementia globally.
Current treatments rely on antibody-based immunotherapy, which has limited cognitive benefits and risks.
CD4+ T cells show promise in reducing AD pathology and improving cognition in mouse models.
Researchers engineered CD4+ T cells with chimeric antigen receptors (CARs) targeting amyloid-β aggregates.
CAR-T cells reduced amyloid deposition in the dura and brain parenchyma.
Treatment also expanded and recruited endogenous CD4+ T cells into the brain.
The study supports CAR-T cell therapy as a potential universal treatment for AD.
The approach may modify amyloid pathology and reshape the CNS immune landscape.

Hasty Briefsbeta